Literature DB >> 9425802

Epidemiology of onychomycosis in special-risk populations.

L A Levy1.   

Abstract

A person's susceptibility to onychomycosis and the course of the disease once the nails are infected are functions of the interaction of the fungal agent, the host, and environmental factors. The disease is reported to have an overall prevalence of 2% to 13%, but the prevalence is much higher in certain populations, such as older people and those with immunosuppressive conditions. Although onychomycosis may be merely a nuisance and an embarrassment for healthy individuals, some morbidity is seen with all population groups, but especially high-risk patients: diabetics, patients infected with human immunodeficiency virus (HIV), patients with acquired immunodeficiency syndrome (AIDS), and patients with other types of immunosuppression (eg, transplant recipients and patients on long-term corticosteroid therapy). Whether the increased prevalence of onychomycosis in the elderly (up to 30% by age 60) is related to changes in immune function is not known.

Entities:  

Mesh:

Year:  1997        PMID: 9425802     DOI: 10.7547/87507315-87-12-546

Source DB:  PubMed          Journal:  J Am Podiatr Med Assoc        ISSN: 1930-8264


  13 in total

Review 1.  Onychomycosis in the elderly.

Authors:  A K Gupta
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.

Authors:  Tsuyoshi Shimamura; Nobuo Kubota; Saori Nagasaka; Taku Suzuki; Hideki Mukai; Kazutoshi Shibuya
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

Review 3.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  An overview of fungal infections.

Authors:  G Garber
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Onychomycosis incidence in type 2 diabetes mellitus patients.

Authors:  Patricia Manzano-Gayosso; Francisca Hernández-Hernández; Luis Javier Méndez-Tovar; Yanni Palacios-Morales; Erika Córdova-Martínez; Elva Bazán-Mora; Rubén López-Martinez
Journal:  Mycopathologia       Date:  2008-03-29       Impact factor: 2.574

Review 6.  Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy.

Authors:  Boni E Elewski; Antonella Tosti
Journal:  J Clin Aesthet Dermatol       Date:  2015-11

7.  A preformulation strategy for the selection of penetration enhancers for a transungual formulation.

Authors:  Biji Palliyil; David B Lebo; Pankil R Patel
Journal:  AAPS PharmSciTech       Date:  2013-04-10       Impact factor: 3.246

Review 8.  The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature.

Authors:  Aditya K Gupta; Rachel R Mays
Journal:  Skin Appendage Disord       Date:  2018-02-13

9.  Polishing the Therapy of Onychomycosis Induced by Candida spp.: Amphotericin B-Loaded Nail Lacquer.

Authors:  Aleph M S Souza; Renato C A Ribeiro; Gleyse K L O Pinheiro; Francisco I Pinheiro; Wógenes N Oliveira; Luanda B F C Souza; André L Silva; Lucas Amaral-Machado; Éverton N Alencar; Guilherme M Chaves; Eryvaldo S T Egito
Journal:  Pharmaceutics       Date:  2021-05-24       Impact factor: 6.321

10.  Antidermatophytic Activity of Pogostemon parviflorus Benth.

Authors:  Batool Sadeghi-Nejad; Subhash Sadhu Deokule
Journal:  Iran J Pharm Res       Date:  2010       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.